iCAD (NASDAQ:ICAD – Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $4.72 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
iCAD Price Performance
Shares of ICAD stock opened at $2.33 on Tuesday. iCAD has a 12-month low of $1.18 and a 12-month high of $3.78. The firm has a market capitalization of $61.84 million, a price-to-earnings ratio of -17.92 and a beta of 1.95. The business has a 50 day simple moving average of $2.63 and a 200 day simple moving average of $2.04.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, February 20th.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Further Reading
- Five stocks we like better than iCAD
- How to Invest in Insurance Companies: A Guide
- Can TikTok Stock Picks Really Make You Rich?
- Why Invest in 5G? How to Invest in 5G Stocks
- The “Quality” Rotation: Back to Basics Investing
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
